RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Amneal Pharmaceuticals Stock

Amneal Pharmaceuticals EBIT 2024

Amneal Pharmaceuticals EBIT

515.55 M USD

Ticker

AMRX

ISIN

US03168L1052

WKN

A2JLMD

In 2024, Amneal Pharmaceuticals's EBIT was 515.55 M USD, a 87.58% increase from the 274.85 M USD EBIT recorded in the previous year.

The Amneal Pharmaceuticals EBIT history

YEAREBIT (undefined USD)
2028e-
2027e420.44
2026e553.96
2025e528.39
2024e515.55
2023274.85
2022199.3
2021216.4
2020145.7
2019-12.7
2018284.5
2017-153.3
2016-433.4
201587.9
201497
201324.1
201297.2
2011107.1
2010399.7
200985.1
200810.4
200786.5
20061
20052.1
2003-13.5

Amneal Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Amneal Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Amneal Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Amneal Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Amneal Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Amneal Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Amneal Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Amneal Pharmaceuticals’s growth potential.

Amneal Pharmaceuticals Revenue, EBIT and net profit per share

DateAmneal Pharmaceuticals RevenueAmneal Pharmaceuticals EBITAmneal Pharmaceuticals Net Income
2028e2.83 B undefined0 undefined289.64 M undefined
2027e2.74 B undefined420.44 M undefined261.3 M undefined
2026e2.82 B undefined553.96 M undefined218.28 M undefined
2025e2.71 B undefined528.39 M undefined203.06 M undefined
2024e2.61 B undefined515.55 M undefined182.6 M undefined
20232.39 B undefined274.85 M undefined-83.99 M undefined
20222.21 B undefined199.3 M undefined-129.99 M undefined
20212.09 B undefined216.4 M undefined10.62 M undefined
20201.99 B undefined145.7 M undefined91.1 M undefined
20191.63 B undefined-12.7 M undefined-361.9 M undefined
20181.66 B undefined284.5 M undefined-20.9 M undefined
2017775.8 M undefined-153.3 M undefined-469.3 M undefined
2016824.4 M undefined-433.4 M undefined-472 M undefined
2015860.5 M undefined87.9 M undefined39 M undefined
2014596 M undefined97 M undefined57.4 M undefined
2013511.5 M undefined24.1 M undefined101.3 M undefined
2012581.7 M undefined97.2 M undefined55.9 M undefined
2011512.9 M undefined107.1 M undefined65.5 M undefined
2010879.5 M undefined399.7 M undefined250.4 M undefined
2009358.4 M undefined85.1 M undefined50.1 M undefined
2008210.1 M undefined10.4 M undefined16 M undefined
2007273.8 M undefined86.5 M undefined125.4 M undefined
2006135.2 M undefined1 M undefined-12 M undefined
2005112.4 M undefined2.1 M undefined-5.8 M undefined
200358.8 M undefined-13.5 M undefined-14.2 M undefined

Amneal Pharmaceuticals stock margins

The Amneal Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Amneal Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Amneal Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Amneal Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Amneal Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Amneal Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Amneal Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Amneal Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Amneal Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Amneal Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Amneal Pharmaceuticals Margin History

Amneal Pharmaceuticals Gross marginAmneal Pharmaceuticals Profit marginAmneal Pharmaceuticals EBIT marginAmneal Pharmaceuticals Profit margin
2028e35.79 %0 %10.25 %
2027e35.79 %15.33 %9.53 %
2026e35.79 %19.64 %7.74 %
2025e35.79 %19.52 %7.5 %
2024e35.79 %19.75 %6.99 %
202335.79 %11.48 %-3.51 %
202235.97 %9.01 %-5.88 %
202137.81 %10.34 %0.51 %
202033.27 %7.31 %4.57 %
201929.46 %-0.78 %-22.25 %
201843.62 %17.11 %-1.26 %
201718.54 %-19.76 %-60.49 %
2016-18.33 %-52.57 %-57.25 %
201541.8 %10.21 %4.53 %
201452.95 %16.28 %9.63 %
201341.54 %4.71 %19.8 %
201248.58 %16.71 %9.61 %
201150.36 %20.88 %12.77 %
201061.32 %45.45 %28.47 %
200952.48 %23.74 %13.98 %
200856.21 %4.95 %7.62 %
200760.66 %31.59 %45.8 %
200646.6 %0.74 %-8.88 %
200548.04 %1.87 %-5.16 %
200325.51 %-22.96 %-24.15 %

Amneal Pharmaceuticals Aktienanalyse

What does Amneal Pharmaceuticals do?

Amneal Pharmaceuticals Inc is a leading pharmaceutical company headquartered in Bridgewater, New Jersey, USA. It was founded in 2002 by Chirag Patel and Chintu Patel, both of whom were involved in the generic pharmaceutical industry. Amneal specializes in the development, manufacturing, and marketing of high-quality, cost-effective generic and specialty pharmaceuticals for a variety of therapeutic areas. The company's mission is to help patients worldwide by producing and delivering high-quality, cost-effective medications. Amneal operates globally in over 50 countries, with global facilities in India, Ireland, and other countries. The company strives to provide innovation, exceptional service, and reliability to customers and patients worldwide. Over the years, the company has rapidly grown to become a major player in the global pharmaceutical market. It offers a wide range of products, including both generic and specialty pharmaceuticals in numerous therapy areas. These areas include oncology, central nervous system (CNS), gastroenterology, dermatology, immunology, pain management, and many others. Amneal places a strong emphasis on clinical research and development to create innovative medications and therapies that meet the needs of today's patients. The company has multiple research and development centers worldwide, including in Israel, India, and the USA, where it collaborates closely with industry partners to develop new products. Another hallmark of Amneal is its ability to provide high-quality generic pharmaceuticals that meet the needs of customers in different countries and regions. The company manufactures its products to the highest standards and has a strict quality assurance system to ensure that patients can rely on receiving medications of the highest quality and efficacy. Amneal's product line is extensive, encompassing a variety of drugs ranging from simple over-the-counter (OTC) preparations to complex steroids and oncology therapeutics. Some of its key products include Tamoxifen Citrate, Lamotrigine, Methylphenidate Hydrochloride, Warfarin Sodium, Buprenorphine-Naloxone, and many others. Amneal Pharmaceuticals also forms partnerships with other companies to expand and diversify its business model. In 2018, Amneal merged with Impax Laboratories, Inc., a leading pharmaceutical company specializing in the development, manufacturing, and marketing of generic and specialty products for various therapy areas. The merger brought together both companies, creating an entity with a broader product portfolio, a larger global reach, and stronger development and marketing expertise. In summary, Amneal Pharmaceuticals Inc is a leading pharmaceutical company focused on the development and marketing of generic and specialty pharmaceuticals for a variety of therapeutic areas. The company is on a mission to help patients worldwide by producing and delivering high-quality, cost-effective medications. Amneal prioritizes clinical research and development to create innovative medications and therapies, and it has a strict quality assurance system. The company has a wide product range and collaborates closely with other companies to expand its business model and global reach. Amneal Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Amneal Pharmaceuticals's EBIT

Amneal Pharmaceuticals's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Amneal Pharmaceuticals's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Amneal Pharmaceuticals's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Amneal Pharmaceuticals’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Amneal Pharmaceuticals stock

How much did Amneal Pharmaceuticals achieve in EBIT for the current year?

In the current year, Amneal Pharmaceuticals has achieved an EBIT of 515.55 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Amneal Pharmaceuticals.

How has the EBIT of Amneal Pharmaceuticals developed in recent years?

The EBIT of Amneal Pharmaceuticals has increased by 87.577% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Amneal Pharmaceuticals?

The EBIT of Amneal Pharmaceuticals is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Amneal Pharmaceuticals pay?

Over the past 12 months, Amneal Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Amneal Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Amneal Pharmaceuticals?

The current dividend yield of Amneal Pharmaceuticals is .

When does Amneal Pharmaceuticals pay dividends?

Amneal Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Amneal Pharmaceuticals?

Amneal Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Amneal Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Amneal Pharmaceuticals located?

Amneal Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Amneal Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Amneal Pharmaceuticals from 8/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/1/2024.

When did Amneal Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/1/2024.

What was the dividend of Amneal Pharmaceuticals in the year 2023?

In the year 2023, Amneal Pharmaceuticals distributed 0 USD as dividends.

In which currency does Amneal Pharmaceuticals pay out the dividend?

The dividends of Amneal Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Amneal Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Amneal Pharmaceuticals

Our stock analysis for Amneal Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amneal Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.